Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
about
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseasesSafety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis.Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis.Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis.Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis.[Vaccination in patients from Brasília cohort with early rheumatoid arthritis].[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort.Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
P2860
Q26825440-BE6D77CA-ADC9-48B3-8D70-74E1FDD8BA3DQ30360610-4CE676BC-528A-4E88-B6CE-6277EA0173DBQ30420493-F189F271-70DF-4AF0-8A77-DEE7AE1182E8Q30420964-C2C1F441-83E6-4051-A908-4046D5B3FA75Q30421442-9D1A24E6-DF8A-40FD-96FB-AF5401859061Q36367842-04024C40-4DD8-4DE2-9282-F631127EF0DCQ36644797-814B6DB4-9C9B-46EE-904E-F19F40DCD113Q38171461-7336439A-8841-47CE-8E5B-E6856AF8E456Q40061605-1126B4B8-9227-4D50-B06F-62D4912B5CE3Q40172149-015BC1FE-D980-42C8-B8D8-26D441B6A385Q41176187-DB0F47CC-A42C-4156-83AA-F426F43861E9Q43170863-796BD731-2381-4D7D-AE83-F4F38CB30D45Q54249618-ECF5D8FC-FBC4-4990-85D0-AAD5386D457A
P2860
Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reduced seroprotection after p ...... cations for clinical practice.
@ast
Reduced seroprotection after p ...... cations for clinical practice.
@en
type
label
Reduced seroprotection after p ...... cations for clinical practice.
@ast
Reduced seroprotection after p ...... cations for clinical practice.
@en
prefLabel
Reduced seroprotection after p ...... cations for clinical practice.
@ast
Reduced seroprotection after p ...... cations for clinical practice.
@en
P2093
P50
P356
P1476
Reduced seroprotection after p ...... cations for clinical practice.
@en
P2093
Alberto Duarte
Ana C M Ribeiro
Ana Luisa Calich
Carla G S Saad
Celio R Goncalves
Ieda M M Laurindo
Ivan L A França
Jozelio F Carvalho
Julio C B Moraes
Lissiane K N Guedes
P304
P356
10.1136/ARD.2011.152983
P407
P577
2011-08-22T00:00:00Z